The global pulmonary drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to fuel the market growth include a rise in the prevalence of chronic diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease and a rise in tobacco smoking. Pulmonary drug delivery systems deliver drugs to the lung for the treatment of respiratory tract diseases. This route is preferred broadly owing to the non-invasive technique, high blood circulation, large surface area for absorption, and permeability rate. Recent advancements in pulmonary drug delivery devices and methods, rise in gastrointestinal upset, respiratory diseases, and minimum dose requirement are the driving factors that will accelerate the growth of the market during the forecast period. 

Moreover, rising incidences of chronic respiratory diseases will surge the demand for pulmonary drugs. As per the Global Asthma Report 2018, around 339 million people are affected by Asthma globally. The significant increase in the targeted patient pool will promote the demand for pulmonary drugs. Furthermore, R&D associated with the pulmonary drugs coupled with government and non-government initiatives will create lucrative opportunities for the market in the coming years, which in turn are expected to boost the market growth during the forecast period. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to raise awareness about asthma, which will increase the adoption of pulmonary drugs in the treatment of chronic obstructive pulmonary disease (COPD) and asthma, leading to the growth of the global pulmonary drugs market.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co., Inc., and AstraZeneca plc. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pulmonary Drugs Market Report by Segment

By Drug Class 

• Beta-2 Agonists

• Anticholinergic Agents

• Oral and Inhaled Corticosteroids

• Anti-leukotrienes

• Antihistamines

• Monoclonal Antibodies

• Combination Drugs

• Others

By Indication 

• Asthma

• COPD (Chronic Obstructive Pulmonary Disease

• Allergic Rhinitis

• Pulmonary Arterial Hypertension

• Cystic Fibrosis

• Others

By Distribution Channel 

• Hospital Pharmacies

• Retail Pharmacies

• Others

Global Pulmonary Drugs Market by Region